No Data
No Data
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE, OTCQX:ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration ("FDA") that otenaproxesul has been placed on
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
- AAPM is the primary organization for pain medicine physicians in the U.S. Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of
Antibe Therapeutics Non-GAAP EPS of -C$0.08
No Data